The Alzheimer’s Agitation and Psychosis Report
Agitation and psychosis are increasingly recognized as distinct and clinically significant neuropsychiatric syndromes in Alzheimer’s disease, yet remain areas of substantial unmet medical need.
This Report Offers Insight Into:
- The extent of unmet medical need and treatment limitations in Alzheimer’s disease agitation and psychosis.
- The current pipeline and developer landscape, including which mechanisms of action and targets are being prioritized.
- The availability and maturity of preclinical and clinical evidence across agitation and psychosis, as well as upcoming development milestones.
You May Also Be Interested In…
Learn More About Neuroscience
What is Beacon Neuroscience?
- The Most Comprehensive Way to Search the Neuroscience Drug Development Landscape: Unique search ontologies based on Neuroscience drug and trial characteristics
- Market Leading Approach to Neuroscience Preclinical & Clinical Data Curation: Manual curation of key Neuroscience research and development data points by Neuroscience research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Neuroscience company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
